Cyclophosphamide Treatment Options

A collection of 2150 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.

Home

All Treatments

Cyclophosphamide

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

NCT00486668

Unknown

The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. Trastuzumab will also be given to all patients after surgery. The study will also evaluate the toxi... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/03/2016

Locations: MBCCOP, Gulf Coast, Mobile, Alabama +109 locations

MBCCOP, Gulf Coast, Mobile, Alabama

Scripps Cancer Center-San Diego, La Jolla, California

University of California, Irvine Medical Center, Long Beach, California

Pacific Shores Medical Group, Long Beach, California

St. Joseph Hospital, Orange, California

Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs, California

Stanford University Medical Center, Palo Alto, California

Sutter Medical Center, Sacramento, California

Kaiser Permanente-San Diego, San Diego, California

Santa Rosa Memorial Hospital, Santa Rosa, California

Kaiser Permanente-Vallejo, Vallejo, California

University of Colorado Cancer Center, Aurora, Colorado

Memorial Hospital, Colorado Springs, Colorado

Kaiser Permanente-Franklin, Denver, Colorado

CCOP-Colorado Cancer Research Prog. Inc.(Administrative Only), Denver, Colorado

Kaiser Permanente Rock Creek, Lafayette, Colorado

Hartford Hospital, Hartford, Connecticut

Eastern Connecticut Hematology & Oncology Associates, Norwich, Connecticut

Sibley Memorial Hospital, Washington, District of Columbia

MD Anderson Cancer Center, Orlando, Florida

Phoebe Putney Memorial Hospital, Albany, Georgia

MBCCOP, Medical College of Georgia Research Institute, Augusta, Georgia

University of Hawaii, Honolulu, Hawaii

Kaiser Permanente Hawaii - Moanalua Med Center, Honolulu, Hawaii

Kootenai Cancer Center, Coeur D'Alene, Idaho

Rush University Medical Center, Chicago, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Cancer Institute at Alexian Brothers Hospital Network, Elk Grove, Illinois

Edward Hospital, Naperville, Illinois

Edward Cancer Center Plainfield, Plainfield, Illinois

CCOP, Central Illinois, Springfield, Illinois

CCOP, Carle Cancer Center, Urbana, Illinois

St. Vincent Hospital and Health Care Center, Indianapolis, Indiana

CCOP, Northern Indiana Cancer Research Consortium, South Bend, Indiana

CCOP, Des Moines, IA, Des Moines, Iowa

University of Iowa, Iowa City, Iowa

CCOP, Sioux Community Cancer consortium, Sioux City, Iowa

CCOP, Wichita KS, Wichita, Kansas

University of Kentucky Medical Center, Lexington, Kentucky

NortonHealtcare Inc., Louisville, Kentucky

CCOP, Ochsner Clinic Foundation, New Orleans, Louisiana

Greater Baltimore Medical Center, Baltimore, Maryland

Franklin Square Hospital Center, Baltimore, Maryland

Boston Medical Center, Boston, Massachusetts

CCOP, Michigan Cancer Research Consortium, Ann Arbor, Michigan

Henry Ford Health System, Detroit, Michigan

Henry Ford Hospital, Detroit, Michigan

CCOP, Grand Rapids Clnical Oncology Program, Grand Rapids, Michigan

CCOP, Kalamazoo, MI, Kalamazoo, Michigan

Michigan State University - Breslin Cancer Center, Lansing, Michigan

CCOP, William Beaumont Hospital, Royal Oak, Michigan

Providence Hospital - Southfield, Southfield, Michigan

Hennepin County Medical Center, Minneapolis, Minnesota

CCOP, Metro-Minnesota, Minneapolis, Minnesota

University of Missouri-Ellis Fischel, Columbia, Missouri

CCOP, Kansas City (Administrative Only), Kansas City, Missouri

CCOP, Ozark Health Ventures LLC, Springfield, Missouri

Saint Louis UniversityHealth Sciences Center, St. Louis, Missouri

CCOP, Heartland Cancer Research, St. Louis, Missouri

CCOP, Montana Cancer Consortium, Billings, Montana

CCOP, Missouri Valley Consortium, Omaha, Nebraska

Cancer Institute of New Jersey, New Brunswick, New Jersey

Newark Beth Israel Medical Center, Newark, New Jersey

New York Oncology Hematology PC-Albany, Albany, New York

Cancer Center at Glens Falls Hospital, Glens Falls, New York

CCOP, Hematology-Oncology Associates of CNY, Syracuse, New York

Alamance Regional Medical Center, Burlington, North Carolina

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

CCOP, Southeast Cancer Control Consortium, Charlotte, North Carolina

Alamance Regional Medical Center - Off site Clinic, Mebane, North Carolina

Wake Forest University School of Medicine, Winston-Salem, North Carolina

Akron City Hospital, Akron, Ohio

Aultman Hospital, Canton, Ohio

Case Western Reserve/University Hospitals-Ireland Cancer Cntr., Cleveland, Ohio

Ohio State University, Columbus, Ohio

CCOP, Columbus, OH, Columbus, Ohio

CCOP, Dayton, OH, Dayton, Ohio

CCOP, Oklahoma, Tulsa, Oklahoma

Lehigh Valley Hospital, Allentown, Pennsylvania

Geisinger Clinic, Danville, Pennsylvania

Hershey Medical Center, Hershey, Pennsylvania

Albert Einstein Healthcare Network, Philadelphia, Pennsylvania

Allegheny General Hospital/Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania

NSABP Foundation, Inc., Pittsburgh, Pennsylvania

University of Pittsburgh, Pittsburgh, Pennsylvania

Western Pennsylvania Hospital, Pittsburgh, Pennsylvania

Mercy Hospital, Scranton, Pennsylvania

Reading Hospital & Medical Center, West Reading, Pennsylvania

CCOP, Main Line Health, Wynnewood, Pennsylvania

CCOP, Upstate Carolina, Spartanburg, South Carolina

Sanford Cancer Center, Souix Falls, South Dakota

Thompson Cancer Survival Center-Dowell Springs, Knoxville, Tennessee

Joe Arrington Cancer Research & Treatment Center, Lubbock, Texas

University of Texas Health Science Center at San Antonio, San Antonio, Texas

MBCCOP, Virginia Commonwealth University, Richmond, Virginia

Puget Sound Oncology Consortium, Seattle, Washington

CCOP, Virginia Mason, Seattle, Washington

CCOP, Northwest, Tacoma, Washington

West Virginia University Hospitals Inc., Morgantown, West Virginia

Camden-Clark Memorial Hospital, Parkersburg, West Virginia

Wheeling Hospital, Wheeling, West Virginia

CCOP, Marshfield Clinic, Marshfield, Wisconsin

Medical College of Wisconsin, Milwaukee, Wisconsin

Odette Cancer Centre, Toronto, Ontario

Royal Victoria Hospital, Montreal, Quebec

Jewish General Hospital, Montreal, Quebec

St. Mary's Hospital Center, Montreal, Quebec

University of Montreal Hospital Group, Montreal, Quebec

Centre Hospitalier Affilie Universitaire De Quebec, Hospital du St-Sacrement, Quebec City, Quebec

MBCCOP, San Juan, Puerto Rico, San Juan, Not set

Conditions: Invasive Breast Cancer

Learn More ›

Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma

NCT01435499

Completed

The primary objective of this study is to evaluate the safety and feasibility of administering an allogeneic GM-CSF-secreting lethally irradiated whole melanoma cell vaccine ("melanoma GVAX"), alone or in combination with low dose cyclophosphamide (CPM), for the adjuvant treatment of patients with surgically resected stage IIB-IV melanoma. Secondarily, the investigators will assess in vitro correlates of anti-melanoma immunization by melanoma GVAX, including serological and cellular immune respo... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2016

Locations: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

Conditions: Melanoma

Learn More ›

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

NCT01468818

Terminated

Background: * The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient with aldesleukin (IL-2) a drug that keeps the white blood cells active. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma. * This study will use chemotherapy to prepare the immune system before this white blood cell treatment. Our prior studies indicate that aldesleukin may not be required for cell transfer. Objectives: - To see if chemotherapy and white blood cell therapy without aldesleukin is a safe and effective treatment for metastatic melanoma. Eligibility: - Individuals at least 18 years of age and less than or equal to 70 years of age with metastatic melanoma. Design: * Work up stage: Patients will be seen as an outpatient at the National Institute of Health (NIH) clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed. * Surgery: If the patients meet all of the requirements for the study they will undergo surgery to remove a tumor that can be used to grow the TIL product. * Leukapheresis: Patients may undergo leukapheresis to obtain additional white blood cells. {Leukapheresis is a common procedure, which removes only the white blood cells from the patient.} * Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the TIL cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment. * Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits will take up to 2 days. Read Less

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

05/19/2016

Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland

Conditions: Metastatic Melanoma, Skin Cancer

Learn More ›

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

NCT02062359

Terminated

Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with melanoma that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying them, and then giving the cells back to the patient. In a previous study, the NCI Surgery Branch used the anti-ESO-1 gene and a type of virus (retrovirus) to make these tumor-fighting cells (anti-ESO-1 cells). About half of the patients who received this treatment experienced shrinking of their tumors. In this study, we are using a slightly different method of producing the anti-ESO-1 cells selected for a specific cell type, which we hope, will be better in making the tumors shrink. Objectives: The purpose of this study is to see if these tumor fighting cells (genetically modified cells) that express the receptor for the ESO-1 molecule on their surface can cause melanoma tumors to shrink and to see if this treatment is safe. Eligibility: -Adults 18 and older with cancer that has the ESO-1 molecule on tumor surfaces Design: * Work up stage: Patients will be seen as an outpatient at the National Institutes of Health (NIH) clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed * Leukapheresis: If the patients meet all of the requirements for the study they will undergo leukapheresis to obtain white blood cells to make the anti ESO-1 cells. {Leukapheresis is a common procedure, which removes only the white blood cells from the patient.} * Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the anti-ESO 1 cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment. Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits take up to 2 days. Read Less

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

05/19/2016

Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland

Conditions: Metastatic Cancer, Metastatic Melanoma

Learn More ›

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

NCT00540644

Completed

The purpose of this study to explore the combination of Revlimid®, oral cyclophosphamide and prednisone (RCP) in patients with newly diagnosed multiple myeloma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/12/2016

Locations: Indiana University Cancer Center, Indianapolis, Indiana

Conditions: Multiple Myeloma

Learn More ›

Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer

NCT00203502

Completed

The main purpose of this study is to find out what effects taking the drug bevacizumab together with two chemotherapeutic agents, docetaxel and cyclophosphamide followed by doxorubicin alone before surgery will on breast cancer. Bevacizumab will be given for twelve weeks in combination with chemotherapy then it ill be held during the administration of doxorubicin. Twenty-eight to fifty-six days after undergoing surgery, all patients will receive nine three-weekly infusions of bevacizumab.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

05/02/2016

Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas

Conditions: Breast Cancer

Learn More ›

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

NCT00546377

Completed

RATIONALE: Pentostatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or c... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

04/07/2016

Locations: Memorial Sloan-Kettering Cancer Center, New York, New York

Conditions: Leukemia, Lymphoma

Learn More ›

T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE

NCT00578461

Terminated

Patients are being asked to participate in this study because they have a cancer in their blood (such as leukemia or lymphoma) or myelodysplastic/myeloproliferative (pre-leukemia). We suggest a treatment that might help them live longer without disease than other treatment plans would. This treatment is known as a stem cell transplant. We believe this may help the patient as it allows us to give much stronger doses of drugs and radiation to kill the diseased cells than we could give without the transplant. We also think that the healthy cells may help fight any diseased cells left after the transplant. Stem Cells are special "mother" cells that are found in the bone marrow (the spongy tissue inside bones), although some are also found in the bloodstream (peripheral blood). As they grow, they become either white blood cells which fight infection, red blood cells which carry oxygen and remove waste products from the organs and tissues or platelets, which enable the blood to clot. For the transplant to take place, we will collect these stem cells from a "donor" (a person who agrees to donate these cells) and give them to the patient. The patient has a type of blood cell cancer or other blood problem that is very hard to cure with standard treatments and they will receive a stem cell transplant (SCT). If they have a brother or sister that is a perfect match and agrees to donate, the stem cells will come from him/her. Before the transplant, two very strong drugs plus total body irradiation will be given to the patient (pre-conditioning). This treatment will kill most of the blood-forming cells in the bone marrow. We will then give the patient the healthy stem cells. Once these healthy stem cells are in the bloodstream they will move to the bone marrow (graft) and begin producing blood cells that will eventually mature into healthy red blood cells, white blood cells and platelets. Also, we will ask permission to draw blood from the patient so that we can measure the number of certain blood cells called T regulatory cells. T regulatory cells are special immune cells that can control or regulate the body's immune response. We want to determine whether T regulatory cells are important participants in graft versus host disease (GVHD), infection and relapse. In GVHD, certain cells from the donated marrow or blood (the graft) attack the body of the transplant patient (the host). GVHD can affect many different parts of the body. The skin, eyes, stomach and intestines are affected most often. GVHD can range from mild to life-threatening. We do not know whether T regulatory cells can modify these conditions. We want to measure these T regulatory cells and learn if these cells do influence these conditions. If we learn that T regulatory cells do affect these conditions, then it may be possible to modify these cells for the benefit of transplant patients. Read Less

Gender:

ALL

Ages:

64 years and below

Trial Updated:

03/24/2016

Locations: Texas Children's Hospital, Houston, Texas

Conditions: Leukemia, Cancer, Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin

Learn More ›

T-Reg Cell Kinetics, Stem Cell Transplant, REGALE

NCT00578539

Terminated

Patients have a type of blood cell disorder that is very hard to cure. We are now suggesting a treatment that might help patients live longer without disease than other treatment plans would. This treatment is known as a stem cell transplant. We believe this may help patients as it allows us to give much stronger doses of drugs and radiation to kill the diseased cells than we could give without the transplant. We also think that the healthy cells may help fight any diseased cells left after the transplant. Stem Cells are special "mother" cells that are found in the bone marrow (the spongy tissue inside bones), although some are also found in the bloodstream (peripheral blood). As they grow, they become either white blood cells which fight infection, red blood cells which carry oxygen and remove waste products from the organs and tissues or platelets, which enable the blood to clot. For the transplant to take place, we will collect these stem cells from a "donor" (a person who agrees to donate these cells) and give them to recipient. Patients do not have a sibling that is a perfect match, so the stem cells will come from a donor who is the best match available. This person may be a close relative or an unrelated person whose stem cells best "matches" the patients, and who agrees to donate stem cells. Before the transplant, two very strong drugs plus total body irradiation will be given to the patient (pre-conditioning). This treatment will kill most of the blood-forming cells in the bone marrow. We will then give the patient the healthy stem cells. Once these healthy stem cells are in the bloodstream they will move to the bone marrow (graft) and begin producing blood cells that will eventually mature into healthy red blood cells, white blood cells and platelets. This research study will also use CAMPATH-1H as a pre-treatment. CAMPATH-1H is an antibody against certain types of blood cells. CAMPATH-1H is important because it stays active in the body for a long time after infusion, which means it may work longer at preventing GvHD symptoms. The stem cell transplant described above is considered to be "standard" treatment. We would like to collect additional blood as described below in order to evaluate how the immune system is recovering. We are asking permission to draw blood from the patient so that we can measure the number of certain blood cells called T regulatory cells. T regulatory cells are special immune cells that can control or regulate the body's immune response. We want to determine whether T regulatory cells are important participants in graft versus host disease (GVHD), infection and relapse. In GVHD, certain cells from the donated marrow or blood (the graft) attack the body of the transplant patient (the host). GVHD can affect many different parts of the body. The skin, eyes, stomach and intestines are affected most often. GVHD can range from mild to life-threatening. We do not know whether T regulatory cells can modify these conditions. We want to measure these T regulatory cells and learn if these cells do influence these conditions. If we learn that T regulatory cells do affect these conditions, then it may be possible to modify these cells for the benefit of transplant patients. Read Less

Gender:

ALL

Ages:

All

Trial Updated:

03/24/2016

Locations: Texas Children's Hospital, Houston, Texas

Conditions: Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Disorders

Learn More ›

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

NCT00578903

Terminated

Patients have been diagnosed with severe Aplastic Anemia that have not responded to treatment with immunosuppressive therapy (drugs that suppress the immune system, for example Steroids). The immune system is the system in the body that helps protect the body and fights bacterial, viral and fungal infections. Research studies have shown that patients with Aplastic Anemia have improved survival (may live longer) after receiving a HLA (Human Leukocyte Antigen) identical sibling (brother and sister) stem cell transplants. Patients who do not have matched siblings can undergo immunosuppressive therapy, which has also shown to improve outcome. Unfortunately patients who do not respond to immunosuppressive therapy usually die. The best chance of survival for these patients is an HLA matched unrelated or mismatched related stem cell transplant as described below. Stem cells are created in the bone marrow. They mature into different types of blood cells that people need including red blood cells which carry oxygen around the body, white blood cells which help fight infections, and platelets which help the blood to clot and prevent bleeding. For a matched unrelated stem cell transplant, stem cells are collected from a person (donor) who is not related to the patient but who has the same type of stem cells. For a mismatched related stem cell transplant, stem cells are collected from a donor who is related to the patient and whose stem cells are almost the same as those of the patient but not exactly. The patient then receives high dose chemotherapy. This chemotherapy kills the stem cells in the patient's bone marrow. Stem cells that have been collected from the donor are then given to the patient to replace the stem cells that have been killed. The major problems associated with these types of stem cell transplants are graft rejection (where the patient's immune system rejects the donor stem cells) and severe graft versus host disease (GVHD), where the donors stem cell reacts against the patient's tissues in the body. Read Less

Gender:

ALL

Ages:

Between 1 minute and 60 years

Trial Updated:

03/24/2016

Locations: Texas Children's Hospital, Houston, Texas +1 locations

Conditions: Aplastic Anemia

Learn More ›

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

NCT01539174

Withdrawn

This phase II trial studies how well giving rituximab together with combination chemotherapy works in treating patients with previously untreated high- or high-intermediate-risk diffuse large B-cell lymphoma (DLBCL). Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, dox... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/01/2016

Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma

Learn More ›

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

NCT00005945

Completed

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different combination chemotherapy regimens to see how well they work in treating children with acute lymphoblastic leukemia.

Gender:

ALL

Ages:

Between 1 year and 9 years

Trial Updated:

02/19/2016

Locations: Phoenix Children's Hospital, Phoenix, Arizona +129 locations

Phoenix Children's Hospital, Phoenix, Arizona

Southern California Permanente Medical Group, Downey, California

City of Hope Comprehensive Cancer Center, Duarte, California

Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California

Children's Hospital Los Angeles, Los Angeles, California

Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California

Children's Hospital Central California, Madera, California

Children's Hospital and Research Center at Oakland, Oakland, California

Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center, Orange, California

Children's Hospital of Orange County, Orange, California

Kaiser Permanente Medical Center - Sacramento, Sacramento, California

Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego, San Diego, California

UCSF Comprehensive Cancer Center, San Francisco, California

Santa Barbara Cottage Hospital, Santa Barbara, California

Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California

General Robert Huyser Cancer Center at David Grant Medical Center, Travis Air Force Base, California

Children's Hospital Cancer Center, Denver, Colorado

Presbyterian - St. Luke's Medical Center, Denver, Colorado

Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut

Yale Comprehensive Cancer Center, New Haven, Connecticut

Alfred I. duPont Hospital for Children, Wilmington, Delaware

Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia

Children's National Medical Center, Washington, District of Columbia

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia

Medical Center of Central Georgia, Macon, Georgia

Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia

Mountain States Tumor Institute - Boise, Boise, Idaho

University of Chicago Cancer Research Center, Chicago, Illinois

University of Illinois Medical Center, Chicago, Illinois

Lutheran General Cancer Care Center, Park Ridge, Illinois

Southern Illinois University School of Medicine, Springfield, Illinois

Riley Children Cancer Center at Riley Hospital for Children, Indianapolis, Indiana

Blank Children's Hospital, Des Moines, Iowa

Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa

Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky

Kosair Children's Hospital, Louisville, Kentucky

MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana

Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland

Baystate Regional Cancer Program at D'Amour Center for Cancer Care, Springfield, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Josephine Ford Cancer Center at Henry Ford Health System, Detroit, Michigan

DeVos Children's Hospital, Grand Rapids, Michigan

Bronson Methodist Hospital, Kalamazoo, Michigan

Breslin Cancer Center at Ingham Regional Medical Center, Lansing, Michigan

CCOP - Beaumont, Royal Oak, Michigan

William Beaumont Hospital - Royal Oak, Royal Oak, Michigan

St. Mary's - Duluth Clinic Cancer Center, Duluth, Minnesota

Children's Hospitals and Clinics - Minneapolis/St. Paul, Minneapolis, Minnesota

University of Minnesota Cancer Center, Minneapolis, Minnesota

Mayo Clinic Cancer Center, Rochester, Minnesota

Children's Mercy Hospital, Kansas City, Missouri

Children's Hospital of Omaha, Omaha, Nebraska

UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska

Sunrise Hospital and Medical Center, Las Vegas, Nevada

St. Barnabas Medical Center, Livingston, New Jersey

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey

Newark Beth Israel Medical Center, Newark, New Jersey

St. Joseph's Hospital and Medical Center, Paterson, New Jersey

Valerie Fund Children's Center at Atlantic Health, Summit, New Jersey

Cancer Center of Albany Medical Center, Albany, New York

Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York

Brooklyn Hospital Center, Brooklyn, New York

SUNY Downstate Medical Center, Brooklyn, New York

Brookdale University Hospital and Medical Center, Brooklyn, New York

Comprehensive Cancer Center at Maimonides Medical Center, Brooklyn, New York

Schneider Children's Hospital, New Hyde Park, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

New York Weill Cornell Cancer Center at Cornell University, New York, New York

Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York

Long Island Cancer Center at Stony Brook University Hospital, Stony Brook, New York

SUNY Upstate Medical University Hospital, Syracuse, New York

New York Medical College, Valhalla, New York

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina

Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina

Dakota Cancer Institute at Innovis Health - Dakota Clinic, Fargo, North Dakota

Meritcare Roger Maris Cancer Center, Fargo, North Dakota

Children's Hospital Medical Center of Akron, Akron, Ohio

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio

Columbus Children's Hospital, Columbus, Ohio

Children's Medical Center - Dayton, Dayton, Ohio

Toledo Children's Hospital, Toledo, Ohio

St. Vincent Mercy Medical Center, Toledo, Ohio

CCOP - Columbia River Oncology Program, Portland, Oregon

Doernbecher Children's Hospital at Oregon Health & Science University, Portland, Oregon

Geisinger Medical Center, Danville, Pennsylvania

Children's Hospital at Milton S. Hershey Medical Center, Hershey, Pennsylvania

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Sioux Valley Hospital and University of South Dakota Medical Center, Sioux Falls, South Dakota

East Tennessee State University Cancer Center at Johnson City Medical Center, Johnson City, Tennessee

East Tennessee Children's Hospital, Knoxville, Tennessee

Vanderbilt Children's Hospital, Nashville, Tennessee

Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas

Children's Hospital of Austin, Austin, Texas

Medical City Dallas Hospital, Dallas, Texas

MD Anderson Cancer Center at University of Texas, Houston, Texas

Covenant Children's Hospital, Lubbock, Texas

MBCCOP - South Texas Pediatrics, San Antonio, Texas

Methodist Cancer Center at Methodist Specialty and Transplant Hospital, San Antonio, Texas

CCOP - Scott and White Hospital, Temple, Texas

Children's Hospital of the King's Daughters, Norfolk, Virginia

Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington

Group Health Central Hospital, Seattle, Washington

Deaconess Medical Center, Spokane, Washington

Mary Bridge Children's Hospital and Health Center, Tacoma, Washington

West Virginia University - Robert C. Byrd Health Sciences Center - Charleston Division, Charleston, West Virginia

Cabell Huntington Hospital, Huntington, West Virginia

Bellin Memorial Hospital, Green Bay, Wisconsin

Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center, La Crosse, Wisconsin

University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin

Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin

CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin

Sydney Children's Hospital, Randwick, New South Wales

Royal Children's Hospital, Brisbane, Queensland

Princess Margaret Hospital for Children, Perth, Western Australia

British Columbia Children's Hospital, Vancouver, British Columbia

CancerCare Manitoba, Winnipeg, Manitoba

Janeway Children's Health and Rehabilitation Centre, St. John's, Newfoundland and Labrador

IWK Health Centre, Halifax, Nova Scotia

Children's Hospital of Western Ontario, London, Ontario

Allan Blair Cancer Centre at Pasqua Hospital, Regina, Saskatchewan

Saskatoon Cancer Centre, Saskatoon, Saskatchewan

Starship Children's Health, Auckland, Not set

Swiss Pediatric Oncology Group Bern, Bern, Not set

Swiss Pediatric Oncology Group Geneva, Geneva, Not set

Swiss Pediatric Oncology Group Lausanne, Lausanne, Not set

Conditions: Leukemia

Learn More ›

Browse by State

Cyclophosphamide treatment options in Alabama

Cyclophosphamide treatment options in Alaska

Cyclophosphamide treatment options in Arizona

Cyclophosphamide treatment options in Arkansas

Cyclophosphamide treatment options in California

Cyclophosphamide treatment options in Colorado

Cyclophosphamide treatment options in Connecticut

Cyclophosphamide treatment options in Delaware

Cyclophosphamide treatment options in District of Columbia

Cyclophosphamide treatment options in Florida

Cyclophosphamide treatment options in Georgia

Cyclophosphamide treatment options in Hawaii

Cyclophosphamide treatment options in Idaho

Cyclophosphamide treatment options in Illinois

Cyclophosphamide treatment options in Indiana

Cyclophosphamide treatment options in Iowa

Cyclophosphamide treatment options in Kansas

Cyclophosphamide treatment options in Kentucky

Cyclophosphamide treatment options in Louisiana

Cyclophosphamide treatment options in Maine

Cyclophosphamide treatment options in Montana

Cyclophosphamide treatment options in Nebraska

Cyclophosphamide treatment options in Nevada

Cyclophosphamide treatment options in New Hampshire

Cyclophosphamide treatment options in New Jersey

Cyclophosphamide treatment options in New Mexico

Cyclophosphamide treatment options in New York

Cyclophosphamide treatment options in North Carolina

Cyclophosphamide treatment options in North Dakota

Cyclophosphamide treatment options in Ohio

Cyclophosphamide treatment options in Oklahoma

Cyclophosphamide treatment options in Oregon

Cyclophosphamide treatment options in Maryland

Cyclophosphamide treatment options in Massachusetts

Cyclophosphamide treatment options in Michigan

Cyclophosphamide treatment options in Minnesota

Cyclophosphamide treatment options in Mississippi

Cyclophosphamide treatment options in Missouri

Cyclophosphamide treatment options in Pennsylvania

Cyclophosphamide treatment options in Rhode Island

Cyclophosphamide treatment options in South Carolina

Cyclophosphamide treatment options in South Dakota

Cyclophosphamide treatment options in Tennessee

Cyclophosphamide treatment options in Texas

Cyclophosphamide treatment options in Utah

Cyclophosphamide treatment options in Vermont

Cyclophosphamide treatment options in Virginia

Cyclophosphamide treatment options in Washington

Cyclophosphamide treatment options in West Virginia

Cyclophosphamide treatment options in Wisconsin

Cyclophosphamide treatment options in Wyoming